[1] Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64: 9-29.
[2] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2012, 379: 1245-1255.
[3] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53: 1020-1022.
[4] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Col-laboration’s tool for assessing risk of bias in randomised trials[J]. BMJ, 2011, 343: d5928.
[5] Der Simonian R, Kacker R. Random- effects model for meta- analysis of clinical trials:an update[J]. Contemp Clin Trials, 2007, 28:105-114.
[6] Izumi R, Shimizu K, Iyobe T, et al. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma[J]. Hepatology(Baltimore), 1994,20: 295-301.
[7] Peng BG, He Q, Li JP, et al. Adjuvant transcatheter arterial chemo- embolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. Am J Surg, 2009, 198: 313-318.
[8] Li Q, Wang J, Sun Y, et al. Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis: a randomized study[J]. World J Surg, 2006, 30:2004-2011.
[9] Li JQ, Zhang YQ, Zhang WZ, et al. Randomized study of chemoe-mbolization as an adjuvant therapy for primary liver carcinoma after hepatectomy[J]. J Cancer Res Clin Oncol, 1995, 121: 364-366.
[10] Zhong C, Guo RP, Li JQ, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembo-lization versus hepatectomy alone for stage IIIA hepatocellular carcinoma[J]. J J Cancer Res Clin Oncol, 2009, 135: 1437-1445.
[11] 冯 鹏, 林桂宇. 辅助性肝动脉化疗栓塞对原发性肝细胞癌切除术后复发的影响[J]. 中华肝胆外科杂志, 2016, 22: 797-801.
[12] 余正平, 徐正铿, 周为中, 等. 原发性肝癌根治术后辅助肝动脉栓塞化疗预防肝内复发的疗效[J]. 实用医学杂志, 2009,25: 1819-1821.
[13] 徐 峰,黄杨卿, 李叶晟, 等. 小肝细胞癌术后是否常规需要辅助性肝动脉插管化疗栓塞的随机对照研究[J]. 第二军医大学学报, 2012, 33: 274-279.
[14] Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoem-bolization for participants with hepatocellular carcinoma: a meta-analysis[J]. Hepatol Res, 2010, 40: 943-953.
[15] Liao M, Zhu Z, Wang H, et al. Adjuvant transarterial chemoem-bolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis[J]. Scand J Gastroenterol, 2017,52: 624- 634.
[16] Cheng YC, Chen TW, Fan HL, et al. Transarterial chemoembolization for intrahepatic multiple recurrent HCC after liver resection or transplantation[J] Ann Transplant, 2014, 19: 309-316.
[17] Bhargava P, Gammon DC, Kim D, et al. Chemoembolization (CE) with carboplatin and doxorubicin for hepatocellular cancer (HCC): introduction of a novel combination and preliminary results[J]. J Clin Oncol, 2004, 22: 4275.
[18] 赵广生, 徐 克, 梁松年, 等. 原发性肝癌TACE术后严重并发症原因及预防[J]. 介入放射学杂志, 2008, 17: 773-775.
[19] 张岳林, 孙军辉, 聂春晖, 等. 肝动脉化疗栓塞次数对肝癌根治术后复发的影响[J]. 中国肿瘤临床, 2013, 40: 975- 978.